医学
公式-5D
可视模拟标度
生活质量(医疗保健)
肺功能测试
间质性肺病
特发性肺纤维化
物理疗法
最小临床重要差异
肺
队列
内科学
外科
疾病
随机对照试验
健康相关生活质量
护理部
作者
Amy Po Yu Tsai,Seo Am Hur,Alyson W. Wong,Mohsen Safavi,Deborah Assayag,Kerri A. Johannson,Julie Morisset,Charlene D. Fell,Jolene H. Fisher,H. Manganas,Shane Shapera,Gerard Cox,Andrea S. Gershon,Nathan Hambly,Nasreen Khalil,Teresa To,Pearce Wilcox,Andrew J. Halayko,Martin Kolb,Christopher J. Ryerson
出处
期刊:Thorax
[BMJ]
日期:2020-10-06
卷期号:76 (1): 37-43
被引量:40
标识
DOI:10.1136/thoraxjnl-2020-214944
摘要
Rationale The European Quality of Life 5-Dimensions 5-Levels questionnaire (EQ-5D-5L) is a multidimensional patient-reported questionnaire that supports calculation of quality-adjusted life-years. Our objectives were to demonstrate feasibility of use and to calculate the minimum important difference (MID) of the EQ-5D-5L and its associated visual analogue scale (EQ-VAS) in patients with fibrotic interstitial lung disease (ILD). Methods Patients who completed the EQ-5D-5L were identified from the prospective multicentre CAnadian REgistry for Pulmonary Fibrosis. Validity, internal consistency and responsiveness of the EQ-5D-5L were assessed, followed by calculation of the MID for the EQ-5D-5L and EQ-VAS. Anchor-based methods used an unadjusted linear regression against pulmonary function tests (PFTs) and dyspnoea and other quality of life questionnaires. Distribution-based method used one-half SD and SE measurement (SEM) calculations. Results 1816 patients were analysed, including 472 (26%) with idiopathic pulmonary fibrosis. EQ-5D-5L scores were strongly correlated with the dyspnoea and other quality of life questionnaires and weakly associated with PFTs. The estimated MID for EQ-5D-5L ranged from 0.0050 to 0.054 and from 0.078 to 0.095 for the anchor-based and distribution-based methods, respectively. The MID for EQ-VAS ranged from 0.5 to 5.0 and from 8.0 to 9.7 for the anchor-based and distribution-based methods. Findings were similar across ILD subtypes, sex and age. Conclusion We used a large and diverse cohort of patients with a variety of fibrotic ILD subtypes to suggest validity and MID of both the EQ-5D-5L and EQ-VAS. These findings will assist in designing future clinical trials and supporting cost-effectiveness analyses of potential treatments for patients with fibrotic ILD.
科研通智能强力驱动
Strongly Powered by AbleSci AI